ALZN: Rasio kapitalisasi marang pendapatan Alzamend Neuro, Inc.
The potential of Alzamend Neuro, Inc. (ALZN) is based on insurance fund payouts for dementia therapy. Innovative cellular vaccines and lithium developments confirm the firm's scientific status, although the speculative pipeline is already priced in. The GURU.Markets terminal displays the company's P/S chart, where the P/S price action reflects the business value relative to revenue, and the current level is .
Alzamend Neuro, Inc. (ALZN) - rincian metrik lan laporan keuangan
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- rincian valuasi buku bisnis:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Modal Alzamend Neuro, Inc.|ALZN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal alzamend.com|ALZN - Utang perusahaan|Rasio utang marang aset resik Alzamend|ALZN - Utang jangka dawa perusahaan|Utang jangka cendhak Alzamend Neuro|Rasio jangkoan perantara alzamend.com
- informasi bathi lan kelipatan valuasi:
ALZN - Bathi resik|Prakiraan bathi perusahaan Alzamend Neuro, Inc.|ALZN - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep alzamend.com|ALZN - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Alzamend|ALZN - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Alzamend Neuro|ALZN - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan alzamend.com|ALZN - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Alzamend Neuro, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Alzamend Neuro Inc., ALZN
Institutional capital maintains a cautious valuation of Alzamend Neuro, Inc. (ALZN), as the high emotional attachment of retail investors to the fight against Alzheimer's disease often inflates share prices relative to actual earnings. By analyzing the P/S ratio dynamics, an investor can observe the relationship between market capitalization and annual revenue, which helps determine the premium paid for the future success of clinical trials and assess the fundamental stability of the asset.
Pesaing Alzamend Neuro, Inc.
biogen.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S NBIX (Neurocrine Biosciences, Inc.)|RGC: Rasio kapitalisasi marang pendapatan|AXSM: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Corp)|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan VKTX|SUPN (Supernus) - Multiplikator P/S|Rega marang dodolan Catalyst Pharma CPRX|Kapitalisasi marang pendapatan DNLI (Denali Therapeutics Inc)|Multiplikator P/S Harmony Corp (HRMY)|Rasio rega marang pendapatan Biohaven Ltd. BHVN|Rasio kapitalisasi pasar marang pendapatan AMLX|TRVI - Rasio rega marang pendapatan|Rega marang dodolan Praxis Precision Medicines Inc|AVXL (Anavex Corp) - Kapitalisasi marang pendapatan|CeriBell EEG - Rasio kapitalisasi pasar marang pendapatan|PRTA (Prothena Biosciences) - Multiplikator P/S|Alector Therapeutics (ALEC) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Annexon (ANNX)|omeros.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S NGNE (Neurogene Corp)|ACIU - Kapitalisasi marang pendapatan|VYGR: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan neumoratx.com NMRA|SCLX: Multiplikator P/S|Tevogen Bio Holdings Inc. (TVGN) - Multiplikator P/S|Rasio rega marang pendapatan Alpha Cognition Inc|Rasio rega marang pendapatan CGTX|Kapitalisasi marang pendapatan IKT (Inhibikase Therapeutics)|SAVA: Rasio rega marang dodolan|Rasio rega marang pendapatan Assertio ASRT|COYA: Rasio kapitalisasi marang pendapatan|VTGN - Rasio rega marang pendapatan|OVID (Ovid Therapeutics Inc.) - Rasio kapitalisasi marang pendapatan|ABOS: Multiplikator P/S|Rega marang dodolan cervomed.com (CRVO)|Kapitalisasi marang pendapatan ATHE|Multiplikator P/S Clene Nanomedicine|Rasio rega marang pendapatan PepGen Inc. (PEPG)|JUNS (Jupiter Neurosciences, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Relmada Therapeutics RLMD|annovisbio.com (ANVS) - Rega marang dodolan|Grace Tx - Multiplikator P/S|AIFF - Multiplikator P/S|anewmeds.com (KLTO) - Rasio rega marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan RVPH|MetaVia, Inc. - Rasio rega marang dodolan|Multiplikator P/S NRXS|Multiplikator P/S heliusmedical.com (HSDT)|Rasio rega marang pendapatan Passage Bio PASG|NEUP - Kapitalisasi marang pendapatan|Minerva Neurosciences - Multiplikator P/S|Rega marang dodolan athira.com|Addex Therapeutics Ltd (ADXN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CYCN|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan KTTA (Pasithea)|Kapitalisasi marang pendapatan CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan BrainStorm Cell Therapeutics BCLI|CARA: Rasio kapitalisasi marang pendapatan|Chromocell Therapeutics Corporation - Multiplikator P/S|Rega marang dodolan Eliem Therapeutics|ITCI (intracellulartherapies.com) - Kapitalisasi marang pendapatan|longboardpharma.com (LBPH) - Multiplikator P/S|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan NeuroBo (NRBO)|SAGE - Rega marang dodolan|Synaptogenix, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan TRVN|Vigil Neuro - Multiplikator P/S|Koefisien rega marang pendapatan anewmeds.com WENA|Cerevel (CERE) - Rasio rega marang pendapatan
